Complain about a product or service

Guidant Settles Defibrillator Charges For $16.7 Million

Thirty-six states sued company over wiring defects

September 1, 2007

• Device Maker Charged With Unlawful Clinical Trials • Medtronic To Disclose Payments To Doctors • Medtronic Withdaws Defibrillator Wires • Guidant Settles Defibrillator Charges For $16.7 Million • Court Orders Guidant To Release Documents • FDA Warns Guidant About Its Heart Devices • Spitzer Sues Guidant for Hiding Defibrillator Defect • FDA Report Addresses Heart Device Malfunctions • Potentially Harmful Medical Devices Should Be Recalled, Public Citizen Tells FDA • FDA Knew Of Pacemaker Problems Before Recall • Guidant To Resume Defibrillator Sales • Guidant Recalls Pacemakers • Guidant Pacemakers May Be Recalled • FDA Upgrades Guidant Recalls • Guidant Finds More Defibrillator Problems • FDA Recalls Guidant Implantable Defibrillators • Company Withheld News of Flaw in Defibrillator • Medicare To Cover More Defibrillators

Medical device manufacturer Guidant has agreed to settle a multi-state lawsuit over its Implantable Cardioverter Defibrillator medical device for $16.7 million. The devices were recalled in 2005.

The settlement resolves allegations that Guidant failed to disclose to the medical community wiring failures in Guidant-made ICDs called the Ventak Prizm 2 DR Model 1861. It also resolves allegations that after making modifications to correct the wiring problems in 2002, Guidant continued to sell the original, unmodified devices into 2003.

ICDs are devices that doctors surgically implant in a patient’s chest to monitor for abnormal heart rhythms. If a patient’s heart stops, the ICD delivers an electrical surge to start it again.

The Indianapolis-based Guidant is among the world’s three largest makers of ICDs. Its related corporate entities, Guidant Sales Corporation and Cardiac Pacemakers, Inc., are also party to the settlement.

Currenty, Guidant is conducting a warranty program to provide consumers who wish to replace their Ventak Prizms with a new device at no cost, and to reimburse consumers up to $2,500 for any out-of-pocket expenses they incur with the replacement.

As part of the settlement, Guidant has agreed to extend its warranty program for an additional six months. Of the total $16.7 million being paid by Guidant to the states, approximately $1 million will be used to reimburse warranty program participants for expenses they incur beyond the $2,500 threshold.

“As a result of this agreement, Guidant will create the position of patient safety officer staffed by a physician, and will take other steps to ensure that patient safety is always a priority,” New Jersey Attorney General Anne Milgram said. “Guidant will also be more accountable concerning the performance of its products.”

“We want to make sure this life-saving tool is as safe as possible, and that patients and doctors get the information they need about any safety problems,” added North Carolina Attorney General Roy Cooper.

Cooper and 35 other attorneys general began investigating Guidant when they learned that the company made changes in 2002 to correct a wiring problem that could cause the Prizm to short circuit but continued to sell the old model.

If the Prizm short-circuited, it could fail to deliver a life-saving jump-start to a patient’s heart when needed. Guidant kept selling unmodified Prizms even after making two separate changes to correct the problem, and did not tell doctors or the public until May 2005 that it sold Prizms with wiring problems in 2002 and 2003.

Under terms of the settlement, Guidant has agreed, among other things, to do the following:

• Establish a patient safety advisory board consisting of independent experts to evaluate data concerning ICD performance;

• Establish a patient safety officer position, staffed by a physician whose primary responsibility is to advance ICD patient safety;

• On a quarterly basis, publicly disclose and disseminate specific information, including worldwide failure data, survival probability estimates and current information in the event of any U.S. Food and Drug Administration recall of an ICD;

• Post a notice on its Web site within 30 days of any modification to any of its ICDs to correct a failure pattern;

• Solicit the return of out-of-service ICDs

• Maintain a data system to track the serial numbers, implant dates and removal dates of all ICDs that Guidant distributes in the United States.

Report Your Experience
If you've had a bad experience -- or a good one -- with a consumer product or service, we'd like to hear about it. All complaints are reviewed by class action attorneys and are considered for publication on our site. Knowledge is power! Help spread the word. File your consumer report now.

Share		Follow us on Twitter.